Association of circulating CEACAM1 levels and insulin sensitivity in gestational diabetes mellitus

Yiming Wu †, Zhen Yang ‡, Lingfei Zhu ‡, Qing Su ‡ and Li Qin 1,2*

Abstract

Background: The aim of this study was to estimate the levels of circulating carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in subjects with gestational diabetes mellitus (GDM) and investigate the relationships between CEACAM1 and GDM.

Methods: Circulating CEACAM1 levels were measured by ELISA kit in 70 women with GDM and 70 normal glucose tolerance (NGT) pregnant women. Blood samples were collected to detect fasting plasma glucose (FPG), fasting insulin (FINS) and glycosylated hemoglobin (HbA1c) levels in all participants. Insulin sensitivity index (ISOGTT) was calculated to assess insulin sensitivity. Correlation analysis was performed between serum CEACAM1 levels and other parameters.

Results: Circulating CEACAM1 levels were higher in the GDM group than that in the NGT pregnant group, however, the difference showed no statistical significance (1889.82 ± 616.14 vs 1758.92 ± 433.15 pg/ml, \( p > 0.05 \)). In GDM group, CEACAM1 was positively correlated with ISOGTT (\( R = 0.39, P = 0.001 \)), while negatively with 1 h post-meal plasma insulin level (1hPINS) (\( R = -0.32, P = 0.008 \)), 2 h post-meal plasma insulin level (2hPINS) (\( R = -0.33, P = 0.006 \)) and area under curve of insulin (AUCI) (\( R = -0.36, P = 0.002 \)) when adjusting for maternal age and gestational age.

Conclusions: The present study showed that circulating CEACAM1 levels did not differ in both GDM and NGT groups. However, we found a significant positively correlation between CEACAM1 and insulin sensitivity in the GDM group.

Keywords: Carcinoembryonic antigen-related cell adhesion molecule 1, Gestational diabetes mellitus, Insulin sensitivity

Background

Gestational diabetes mellitus (GDM) is diabetes that is first diagnosed in the second or third trimester of pregnancy that is not clearly either preexisting type 1 or type 2 diabetes (T2DM) [1]. In recent decades, the prevalence of GDM has been increasing worldwide, especially in some developing countries [2]. Due to different diagnostic tests, diagnostic criteria, racial difference and so on, the prevalence of GDM reported in various countries ranged from 1.7 to 37.7% [3, 4]. GDM is a metabolic disorder during pregnancy which results in various adverse acute and chronic complications. Besides, both GDM women and the newborns may have an increased incidence risk of T2DM, obesity as well as metabolic syndrome in the future [5–7]. So far, the fundamental pathogenesis of GDM have not been clearly understood. However, IR is a well-documented hallmark of T2DM and GDM.

Recently, Carcinoembryonic antigen-related cell adhesion molecule one (CEACAM1) has been suggested as a potential regulatory molecules in the pathology of IR.
CEACAM1 also known as CD66a, BGP, belongs to the carcinoembryonic antigen (CEA) family [8]. It expresses highly in liver, but not in classical insulin target peripheral tissues such as white adipose tissue and skeletal muscle [9]. Secreted insulin is mostly cleared in liver. Impairment of insulin clearance can be the primary cause of IR [10]. CEACAM1 is a substrate of the insulin receptor in liver, and it is phosphorylated in response to insulin in hepatocytes and then induces insulin clearance by increasing receptor-mediated endocytosis and degradation [11–13]. Regarding this, we hypothesize that CEACAM1 may play a protective role in the occurrence and development of GDM.

To our knowledge, there were no studies on the associations between CEACAM1 and GDM had been reported in the literature. In the present study, we aimed to investigate the circulating CEACAM1 levels and its possible relationship with GDM.

Methods

Subjects

From May to December 2015, pregnant women routinely tested for GDM with a 75-g oral glucose tolerance test (OGTT) between the 24th and 28th weeks of gestation in Xinhua Hospital Chongming Branch Affiliated to Shanghai Jiao Tong University School of Medicine. Pregnant women with multiple pregnancies, preexisting diabetes, hypertension, thyroid dysfunction or other endocrine diseases, acute or chronic inflammation were excluded. 70 pregnant women were newly diagnosed with GDM (GDM group, n = 70) according to the American Diabetes Association criteria. Another 70 subjects were randomly selected from normal glucose tolerance pregnant women (NGT group, n = 70) in accordance with the random number table. GDM was diagnosed according to the criteria of ADA if one or more plasma glucose levels were elevated during the OGTT with the following threshold glucose levels: fasting ≥ 5.1 mmol/l; 1 h ≥ 10.0 mmol/l; 2 h ≥ 8.5 mmol/l. This study was approved by the Ethics Committee of the hospital and conformed to the provisions of the Declaration of Helsinki. All participants signed the informed consent.

Clinical and biochemical assessment

We inquired and recorded the information of name, age, pre-pregnancy weight, gravidity and parity times, and family history of diabetes from all participants at the first prenatal examination between the 13th and 15th weeks of gestation. Anthropometric measurements including height, bodyweight, abdominal perimeter, and blood pressure were measured in the second trimester. Body mass index (BMI) was calculated as the weight divided by the squared height (kg/m²). Venous blood samples were collected after overnight fasting. The serum specimens were separated and stored at −80°C until analyses were performed. Venous plasma glucose level was measured by glucose oxidase method (ADVIA-1650 Chemistry System, Bayer, Leverkusen, Germany), and glycosylated hemoglobin was measured by high-performance liquid chromatography (BIO-RAD, Laboratories, CA). Serum insulin was measured by chemiluminescent immunoassay (ARCHITECT ci16200 analyzer, Abbott Laboratories, Illinois, USA). Circulating CEACAM1 levels were determined by ELISA kit (R&D Systems, Minneapolis, MN). The sensitivity of the assay was 93 pg/ml with inter- and intra-assay coefficients of variation of <10 and <9%, respectively. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as follows: FPG (mmol/l) × FINS (mU/L)/22.5; insulin sensitivity index (ISOGTT) was calculated as [10,000/√(FPG × FINS × mean glucose × mean insulin)]; HOMA-β reflecting the pancreatic β-cells function was calculated as [FINS × 20/(FPG-3.5)].

Statistical analysis

All analyses were performed using the Social Sciences software version 22.0 (SPSS, Chicago, IL). Measurement data were expressed as mean ± standard deviation (SD) or medians (inter-quartile ranges), comparisons of measurement data among groups were carried out by independent sample t-test method. Enumeration data were expressed by rate, using Chi-square for comparisons. The univariate correlations between CEACAM1 and other parameters were performed both by Pearson’s and Spearman’s correlation analysis with adjustment of maternal age and gestational age. A two-tailed P < 0.05 was considered statistically significant. We calculated the sample size according to a GDM prevalence rate of approximately 8.1% in China [14]. Based on a previous study, the SD of CEACAM1 in healthy persons was 109.7 pg/ml [15]. In our study, 140 subjects including 70 GDM and 70 normal glucose tolerance pregnant subjects were enrolled. Using the current sample, to detect a 55 pg/ml difference with a significance level of 0.05 in GDM and NGT group, the power was 82.3% (α = 0.05), therefore, the sample size was considered to be adequate.

Results

Clinical and biochemical characteristics of the studied groups

As shown in Table 1, compared with NGT group, the GDM group had higher maternal age, FPG, 1hPG, 2hPG, FINS, 1hPINS, 2hPINS, HOMA-IR, AUCG, AUCI, neonatal weight and the percentages of positive family history of diabetes(all P < 0.05), while ISOGTT, △I60/>G60 of GDM group were significantly lower than the NGT group (all P < 0.05). Other parameters including blood pressure, pre-pregnancy BMI, pregnancy BMI, parity times, abdominal perimeter and HOMA-β were
similar among the two groups (all $P > 0.05$). The circulating CEACAM1 levels in GDM group tended to be higher compared to NGT group, but the difference had no statistical significance ($P > 0.05$) (Table 1).

### Table 1 Clinical characteristics and circulating CEACAM1 levels of the groups studied

| Variable          | GDM (n = 70) | NGT (n = 70) | $P$ value |
|-------------------|--------------|--------------|-----------|
| Age, years        | 28.54 ± 4.28 | 26.87 ± 3.79 | 0.016     |
| Gestational age, weeks | 24.66 ± 1.10 | 24.81 ± 1.12 | 0.404     |
| Parity, times     | 1 (1–6)      | 2 (1–4)      | 0.058     |
| BMI-1, kg/m2      | 21.54 ± 3.13 | 21.30 ± 3.00 | 0.605     |
| BMI-2, kg/m2      | 24.35 ± 3.07 | 24.03 ± 3.21 | 0.673     |
| Abdominal perimeter, cm | 91.73 ± 6.17 | 90.20 ± 7.44 | 0.207     |
| SBP, mm/Hg        | 113.40 ± 8.59 | 110.53 ± 8.54 | 0.061     |
| DBP, mm/Hg        | 72.07 ± 6.32  | 70.79 ± 4.98  | 0.214     |
| HbA1c, %          | 5.12 ± 0.76   | 4.96 ± 0.37   | 0.128     |
| FPG, mmol/l       | 4.81 ± 0.68   | 4.36 ± 0.30   | < 0.001   |
| 1hPG, mmol/l      | 9.60 ± 1.57   | 6.94 ± 1.34   | < 0.001   |
| 2hPG, mmol/l      | 8.64 ± 1.55   | 6.26 ± 0.89   | < 0.001   |
| FINS, mU/l        | 4.88 (3.44–6.93) | 3.22 (2.33–4.89) | 0.002     |
| 1hPINS, mU/l      | 35.82 (20.83–46.77) | 21.67 (14.36–31.90) | 0.002     |
| 2hPINS, mU/l      | 32.30 (20.81–57.91) | 23.30 (13.09–32.47) | < 0.001   |
| HOMA-IR           | 1.03 (0.66–1.57) | 0.65 (0.45–0.99) | 0.004     |
| HOMA-β            | 81.79 (60.05–118.38) | 86.91 (54.10–131.61) | 0.524     |
| ISOGTT            | 151.00 (106.78–219.80) | 278.89 (190.63–374.30) | < 0.001   |
| AUCG, mmol/l      | 16.325 ± 2.254 | 12.251 ± 1.622 | < 0.001   |
| AUCI, mU/l        | 55.072 (39.09–75.00) | 33.733 (23.51–54.53) | < 0.001   |
| ΔI60/ΔG60         | 6.00 (3.75–8.01) | 9.21 (4.89–14.56) | 0.001     |
| Neonatal weight, g | 3477.78 ± 356.43 | 3333.13 ± 340.42 | 0.032     |
| Family history of DM, % | 10% | 1.43% | < 0.001 |
| CEACAM1, pg/ml    | 1889.82 ± 616.14 | 1758.92 ± 433.15 | 0.148     |

Note: Data are means ± standard deviation (SD) or medians (inter-quartile range)

Abbreviations: BMI-1 body mass index before pregnancy, BMI-2 body mass index in pregnancy, DBP diastolic blood pressure, SBP systolic blood pressure, FPG fasting plasma glucose, 1hPG 1-hour post-meal plasma glucose, 2hPG 2-h post-meal plasma glucose, FINS fasting insulin level, 1hPINS 1-h post-meal plasma insulin level, 2hPINS 2-h post-meal plasma insulin level, AUCG area under curve of glucose, AUCI area under curve of insulin.

Correlations of circulating CEACAM1 levels with anthropometric and biochemical parameters in GDM group

As shown in Table 2, in GDM group, univariate correlation analysis after adjustment of maternal age and gestational age showed that circulating CEACAM1 levels were positively correlated with ISOGTT ($R = 0.39$, $P = 0.001$), while negatively correlated with 1hPINS ($R = -0.32$, $P = 0.008$), 2hPINS ($R = -0.33$, $P = 0.006$), AUCI ($R = -0.36$, $P = 0.002$), no significant correlations were observed between CEACAM1 and the other parameters ($P > 0.05$).

### Discussion

In our study, we first determined circulating levels of CEACAM1 in GDM women. The important finding of the current study was that circulating CEACAM1 levels were associated with serum insulin levels and ISOGTT in the GDM group. Although circulating CEACAM1 levels were higher in the patients with GDM than that in the NGT group, however, we failed to observe statistically significant difference between two groups.

CEACAM1 protein was implicated in cell proliferation, apoptosis, angiogenesis and immune-regulation during tumor development [16]. In the past years, it had been studied as a tumor marker of different types of cancer. On the other hand, earlier studies indicated that CEACAM1 was also related to some metabolic diseases [17–19]. Previous articles reported that the hepatic CEACAM1 expression was markedly decreased in the severely obese subjects, high grade fatty livers and NASH, but not different between diabetic and non-diabetic persons [20]. Consistent with this study, some researchers also indicated that CEACAM1 mRNA levels were declined significantly in the liver of obese humans and obese rats, as expected, the obese rats then displayed hyperinsulinemia, elevated
body weight, fasting plasma free fatty acid, and plasma and hepatic total triglycerides levels [21, 22]. These studies suggested that the decreased CEACAM1 levels might be an early event in obese subjects occurring at the time of insulin resistance before overt diabetes.

In our study, women with GDM showed higher FPG, FINS and HOMA-IR than the NGT group. This result demonstrated that GDM women were in a hyper-insulin state which was complicated with impaired glucose tolerance. As reported, progressive IR was thought to be the major factor in the pathogenesis of GDM, women with GDM had exaggerated IR compared to healthy pregnant women [23, 24]. While the exact mechanisms of IR were complicated and unclear. CEACAM1 regulated hepatic insulin clearance to maintain normoinsulinemia and insulin sensitivity [25]. So far, there were limited studies that had determined the CEACAM1 levels in pregnancy, and the relationships between GDM and CEACAM1 remained unclear. In regard to this, we conducted correlation analysis between CEACAM1 and metabolic parameters in GDM subjects. In this paper, we observed a strong positive association between circulating CEACAM1 and ISOGTT, while adversely negative correlation with AUCI, 1hPINS and 2hPINS when adjusting for age and gestational age in GDM subjects. These findings indicated that CEACAM1 might be closely related to serum insulin levels as well as insulin sensitivity in GDM women. In accordance with our results, earlier studies on experimental animal models reported that mice with null deletion of CEACAM1 or with liver-specific inactivation of CEACAM1 subsequently developed chronic hyperinsulinemia, insulin resistance, hepatic steatosis and visceral obesity [26–28]. Thus, abnormalities of insulin clearance may induce IR and then the occurrence of various pathological conditions including T2DM and severe obesity. Since CEACAM1 is a cytokine with insulin-sensitizing effects, it is likely that CEACAM1 levels would compensatory increase in GDM women to improve severe IR condition. However, in contrast to our hypothesis, this study observed that CEACAM1 levels were similar in both GDM and NGT group. A recent study reported that circulating CEACAM1 levels were different in the three trimesters during pregnancy, and the lowest levels were observed in the second trimester [29]. Given the fact that our blood samples were collected in the second trimester, it may be an explanation for the result.

The current study included some limitations. Firstly, we didn’t measure the blood lipid profile and analyze the possible associations between CEACAM1 and lipid metabolism. Secondly, we failed to investigate the longitudinal changes of circulating CEACAM1 levels during pregnancy and after delivery.

**Conclusions**

Taken together, the results of this study showed a lack of significant difference in terms of CEACAM1 levels between GDM subjects and normal pregnant women. However, we found a significant positively correlation between CEACAM1 and insulin sensitivity after adjustment of age and gestational age in GDM group. Further studies with larger populations are needed to elucidate the role of CEACAM1 in the pathogenesis of GDM.

**Abbreviations**

CEACAM1: Carcinoembryonic antigen-related cell adhesion molecule 1; GDM: Gestational diabetes mellitus; OGTT: Oral glucose tolerance test; BMI: Body mass index; DBP: Diastolic blood pressure; SBP: Systolic blood pressure; FPG: Fasting plasma glucose; FINS: Fasting insulin level; AUCG: Area under curve of glucose; AUCI: Area under curve of insulin

We thank Ying Xin and Hongxia Gu for their contributions at various stages of this study. We are also grateful to all study participants for their involvement in the study.

**Authors’ contributions**

L.Q. defined the research theme. Y.W., Z.Y., L.Z. performed experiments, collected and analyzed the data and wrote the paper. Q.S. revised of the article for important intellectual content. All authors read and approved the final manuscript.

**Authors’ information**

The information was presented in the homepage.
Funding
This work was supported by Shanghai Science and Technology Commission (1541195320, 10411956600, 14ZR1427400, 15411953200), National Natural Science Foundation of China (81300667, 81370953, 81370953, 81670743), Shanghai Health System Outstanding Young Talents Training Program (XYYQ2013098), Scientific Research Project of Shanghai Health and Family planning commission (201740173).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and all participants signed an informed consent form.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing financial interests.

Received: 30 April 2019 Accepted: 10 May 2020
Published online: 15 May 2020

References
1. Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14–31.
2. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care. 2007;30(Suppl 2):S141–6.
3. Schneider S, Bock C, Wetzel M, Maul H, Looft A. The prevalence of gestational diabetes in advanced economies. J Perinat Med. 2012;40(5):11–20.
4. Simmons D. Epidemiology of Diabetes in Pregnancy. Pract Manual Diabetes Pregnancy. 2017:1–16.
5. Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr Diab Rep. 2016;16(1):7.
6. Nehring L, Chmitorz A, Reulen H, von Kries R, Ensenauer R. Gestational diabetes predicts the risk of childhood overweight and abdominal circumference independent of maternal obesity. Diabet Med. 2013;30(12):1449–56.
7. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. PEDIATRICS. 2005;115(5):e290–6.
8. Barnett TR, Kretschmer A, Austen DA, Goebel SJ, Hart JT, Elting JJ, Kamarc ME. Carcinoembryonic antigens: alternative splicing accounts for the multiple mRNAs that code for novel members of the carcinoembryonic antigen family. J Cell Biol. 1998;140(2):235–42.
9. Najjar SM. Regulation of insulin action by CEACAM1. Trends Endocrinol Metab. 2002;13(8):240–5.
10. Ader M, Stefanovski D, Kim SP, Richey JM, Ionut V, Catalano KJ, Hucking K, Illmerer M, Van Citters G, Hsu IR, et al. Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog. Obesity (Silver Spring). 2014;22(5):1238–45.
11. Najjar SM, Filippone N, Suzuki Y, Ignacio GA, Formisano P, Accili D, Taylor SI. Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endogenous substrate of the insulin receptor tyrosine kinase. Biochemistry. 1995;34(29):9341–9.
12. Formisano P, Najjar SM, Gross CN, Filippone N, Oriente F, Kern-Buell CL, Accili D, Gorden P. Receptor-mediated internalization of insulin. Potential role of pp120/HA4, a substrate of the insulin receptor kinase. J Biol Chem 1995, 270(41):24073–24077.
13. Choice CV, Howard MJ, Poy MN, Hankin MH, Najjar SM: Insulin stimulates pp120 endocytosis in cells co-expressing insulin receptors. J Biol Chem 1998, 273(35):22194–22200.
14. Xu X, Liu Y, Liu D, Li X, Rao Y, Sharma M, Zhao Y: Prevalence and Determinants of Gestational Diabetes Mellitus: A Cross-Sectional Study in China. Int J Environ Res Public Health 2017, 14(12).
15. Yu H, Yu J, Ren Y, Yang Y, Xiao X. Serum CEACAM1 level is associated with diagnosis and prognosis in patients with osteosarcoma. PLoS One. 2016;11(4):e0153601.
16. Beauchemin N, Arbabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3–4):643–71.
17. Heinrich G, Ghadieh HE, Gharem SS, Muruti HT, Rezaei K, Al-Share QY, Bowman TA, Zhang D, Garafolo RS, Yin L, et al. Loss of hepatic CEACAM1: a unifying mechanism linking insulin resistance to obesity and non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2017;8.
18. Russo L, Ghadieh HE, Gharem SS, Al-Share QY, Smiley ZN, Gatwei W, Esakov EL, McInerney MF, Heinrich G, Tong X, et al. Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatic axis. J Lipid Res. 2016;57(12):2163–75.
19. Horst AK, Najjar SM, Wagener C, Tiede G. CEACAM1 in Liver Injury, Metabolic and Immune Regulation. Int J Mol Sci. 2018;19(10).
20. Lee W. The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes. Diagn Pathol. 2011;6:40.
21. Heinrich G, Muturi HT, Rezaei K, Al-Share QY, DeAngelis AM, Bowman TA, Ghadieh HE, Gharem SS, Zhang D, Garafolo RS, et al. Reduced hepatic Carcinoembryonic antigen-related cell adhesion molecule 1 level in obesity. Front Endocrinol (Lausanne). 2017;8:54.
22. Ghadieh HE, Russo L, Muturi HT, Gharem SS, Manaseri IH, Noh HL, Suk S, Kim JK, Hill JW, Najjar SM. Hyperinsulinemia drives hepatic insulin resistance in male mice with liver-specific Ceacam1 deletion independently of lipolysis. Metabolism. 2019;93:33–43.
23. Catalano PM, Itiwans JP, Haukel-de MS, King J. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr. 2003;133(6 Suppl 2):1674–83S.
24. Lain KY, Catalano PM. Metabolic changes in pregnancy. Clin Obstet Gynecol. 2007;50(4):938–48.
25. Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kidd Y, Erickson SK, Najjar SM. CEACAM1 regulates insulin clearance in liver. Nat Genet. 2002;30(3):270–6.
26. DeAngelis AM, Heinrich G, Dai T, Bowman TA, Patel PR, Lee SJ, Hong EG, Jung DY, Assmenn A, Kulkarni RN, et al. Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism. Diabetes. 2008;57(9):2296–303.
27. Xu E, Dubois MA, Leung N, Charbonneau A, Turci L, Avramolou R, DeMarte L, Elchelby M, Steichert T, Levy E, et al. Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance. Endocrinology. 2009;150(8):3503–12.
28. Lee SJ, Heinrich G, Fedorova L, Al-Share QY, Ledford KJ, Fernstrom MA, McInerney MF, Erickson SK, Gatwei W, Najjar SM. Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology. 2008;135(6):2094–95.
29. Mach P, Gellhaus A, Prager M, Moore T, Wennemuth G, Kimmig R, Koninger A, Singer BB. Soluble CEACAM1 and CEACAM6 are differently expressed in blood serum of pregnant women during normal pregnancy. Am J Reprod Immunol. 2017;76(4).

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.